These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 16770292)

  • 61. Selegiline transdermal system in major depressive disorder: profile report.
    Frampton JE; Plosker GL
    CNS Drugs; 2007; 21(6):521-4. PubMed ID: 17521230
    [No Abstract]   [Full Text] [Related]  

  • 62. Monoamine oxidase inhibitors and cardiac anesthesia revisited.
    Noorily SH; Hantler CB; Sako EY
    South Med J; 1997 Aug; 90(8):836-8. PubMed ID: 9258314
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Safety of rasagiline in elderly patients with Parkinson disease.
    Goetz CG; Schwid SR; Eberly SW; Oakes D; Shoulson I;
    Neurology; 2006 May; 66(9):1427-9. PubMed ID: 16682679
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease.
    Ito D; Amano T; Sato H; Fukuuchi Y
    J Neurol; 2001 Jun; 248(6):533-4. PubMed ID: 11499649
    [No Abstract]   [Full Text] [Related]  

  • 65. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
    Robinson DS; Amsterdam JD
    J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
    Van Gerpen JA; Ahlskog JE
    Neurology; 2001 Jul; 57(2):368-9; author reply 369-70. PubMed ID: 11468339
    [No Abstract]   [Full Text] [Related]  

  • 67. Rasagiline.
    Schapira A; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Aug; 4(8):625-6. PubMed ID: 16106586
    [No Abstract]   [Full Text] [Related]  

  • 68. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Roesler R; Quevedo J; Walz R; Bianchin M
    Neurology; 1999 Jun; 52(9):1920-1. PubMed ID: 10371554
    [No Abstract]   [Full Text] [Related]  

  • 69. A randomized, double-blind, placebo-controlled trial of deprenyl and thiotic acid in HIV-associated cognitive impairment.
    Di Rocco A
    Neurology; 1999 Jun; 52(9):1920; author reply 1920-1. PubMed ID: 10371553
    [No Abstract]   [Full Text] [Related]  

  • 70. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A case report of high-dose transdermal selegiline in the treatment of major depressive disorder.
    Ashton AK
    Ann Clin Psychiatry; 2009; 21(1):51-2. PubMed ID: 19239833
    [No Abstract]   [Full Text] [Related]  

  • 72. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
    Amsterdam JD
    J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Selegiline and excess mortality.
    Oakes D
    Clin Neuropharmacol; 1997 Dec; 20(6):542. PubMed ID: 9403228
    [No Abstract]   [Full Text] [Related]  

  • 74. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.
    Pae CU; Patkar AA; Jang S; Portland KB; Jung S; Nelson JC
    CNS Spectr; 2014 Aug; 19(4):324-9. PubMed ID: 24168807
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers.
    Azzaro AJ; VanDenBerg CM; Ziemniak J; Kemper EM; Blob LF; Campbell BJ
    J Clin Pharmacol; 2007 Aug; 47(8):978-90. PubMed ID: 17554106
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Remarkable effect of selegiline (L-deprenyl), a selective monoamine oxidase type-B inhibitor, in a patient with severe refractory depression: a case report.
    Higuchi H; Kamata M; Sugawara Y; Yoshida K
    Clin Neuropharmacol; 2005; 28(4):191-2. PubMed ID: 16062100
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Short review on monoamine oxidase and its inhibitors.
    Kanazawa I
    Eur Neurol; 1994; 34 Suppl 3():36-9. PubMed ID: 7821334
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rasagiline in Parkinson's disease: the show must go on.
    Jost WH
    Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684
    [No Abstract]   [Full Text] [Related]  

  • 80. [Revision of the treatment strategy in Parkinson disease].
    Staal-Schreinemachers AL; Wesseling H; Lakke JP
    Ned Tijdschr Geneeskd; 1986 May; 130(20):914-8. PubMed ID: 3724865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.